Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 277

The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.

Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations

Open access
Muecksch, Frauke, Weisblum, Yiska, Barnes, Christopher O., Schmidt, Fabian, Schaefer-Babajew, Dennis, Wang, Zijun, C. Lorenzi, Julio C., Flyak, Andrew I., DeLaitsch, Andrew T., Huey-Tubman, Kathryn E., Hou, Shurong, Schiffer, Celia A., Gaebler, Christian, Da Silva, Justin, Poston, Daniel, Finkin, Shlomo, Cho, Alice, Cipolla, Melissa, Oliveira, Thiago Y., Millard, Katrina G., Ramos, Victor, Gazumyan, Anna, Rutkowska, Magdalena, Caskey, Marina, Nussenzweig, Michel C., Bjorkman, Pamela J., Hatziioannou, Theodora, Bieniasz, Paul D.·2021·Immunity

Abstract

Antibodies elicited by infection accumulate somatic mutations in germinal centers that can increase affinity for cognate antigens. We analyzed 6 independent groups of clonally related severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) Spike receptor-binding domain (RBD)-specific antibodies from 5 individuals shortly after infection and later in convalescence to determine the impact of maturation over months. In addition to increased affinity and neutralization potency, antibody evolution changed the mutational pathways for the acquisition of viral resistance and restricted neutralization escape options. For some antibodies, maturation imposed a requirement for multiple substitutions to enable escape. For certain antibodies, affinity maturation enabled the neutralization of circulating SARS-CoV-2 variants of concern and heterologous sarbecoviruses. Antibody-antigen structures revealed that these properties resulted from substitutions that allowed additional variability at the interface with the RBD. These findings suggest that increasing antibody diversity through prolonged or repeated antigen exposure may improve protection against diversifying SARS-CoV-2 populations, and perhaps against other pandemic threat coronaviruses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.immuni.2021.07.008

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 89 references

Research works printed but not linked: 2

  1. West, 2021, SARS-CoV-2 lineage B.1.526 emerging in the New York region detected by software utility created to query the spike mutational landscape, bioRxiv
  2. Wu, 2020, A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2, Science, 368, 1274, 10.1126/science.abc2241 · DOI · Paper page

Cited by

See all 277

Metadata

Authors
Muecksch, F., Weisblum, Y., Barnes, C. O., Schmidt, F., Schaefer-Babajew, D., Wang, Z., C. Lorenzi, J. C., Flyak, A. I., DeLaitsch, A. T., Huey-Tubman, K. E., Hou, S., Schiffer, C. A., Gaebler, C., Da Silva, J., Poston, D., Finkin, S., Cho, A., Cipolla, M., Oliveira, T. Y., Millard, K. G., Ramos, V., Gazumyan, A., Rutkowska, M., Caskey, M., Nussenzweig, M. C., Bjorkman, P. J., Hatziioannou, T., & Bieniasz, P. D.
Venue
Immunity
Publisher
Elsevier BV
Published
2021-08
Volume
54
Issue
8
Pages
1853-1868.e7
ISSN
1074-7613 (ISSN-L)
OpenAlex
W3190206472
Cited by
277
References
89
FWCI
17.69
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
  • Burroughs Wellcome Fund
  • Gordon and Betty Moore Foundation
  • NSF
  • National Science Foundation (GRFP DGE-1745301)
  • Howard Hughes Medical Institute
  • Basic Energy Sciences (DE-AC02-c76SF00515)
  • NIGMS (P41GM103393)
  • Rockefeller University (63/021,387)
  • Office of Science
  • National Center for Advancing Translational Sciences (UL1 TR001866)
  • Biological and Environmental Research
  • National Institutes of Health
  • Beckman Institute, California Institute of Technology
  • National Institute of Allergy and Infectious Diseases (2U19AI111825, R01AI78788, P01-AI138938-S1, K99 AI153465, R37-AI64003, HIV-1-pseudotypes)
  • Department of Energy
  • Arnold and Mabel Beckman Foundation
  • Caltech
  • George Mason University

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. https://app.cochat.ai/papers/10.1016/j.immuni.2021.07.008
The paper
Muecksch, F., Weisblum, Y., Barnes, C. O., Schmidt, F., Schaefer-Babajew, D., Wang, Z., C. Lorenzi, J. C., Flyak, A. I., DeLaitsch, A. T., Huey-Tubman, K. E., Hou, S., Schiffer, C. A., Gaebler, C., Da Silva, J., Poston, D., Finkin, S., Cho, A., Cipolla, M., Oliveira, T. Y., . . . Bieniasz, P. D. (2021). Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity. https://doi.org/10.1016/j.immuni.2021.07.008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.